NCT03067753

Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis

Detailed description

A prospective phase II trial was conducted to test the efficacy of monosialoganglioside ganglioside for the treatment of cerebral radiation necrosis

Conditions

• Cerebral Radiation Necrosis

Interventions

Type	Name	Description
DRUG	Monosialoganglioside Ganglioside	Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
DRUG	Methylprednisolone (Steroid Hormone)	Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
DRUG	Prednisolone

Timeline

• Start date: 2016-12-01
• Primary completion: 2019-09-01
• Completion: 2019-09-01
• First posted: 2017-03-01
• Last updated: 2017-03-01

Locations

1 site across 1 country: China